Clients

Actinium Pharmaceuticals, Inc

Company Snapshot: Actinium Pharmaceuticals, Inc

ATNM
Last Change Volume High Low

Company Overview

Actinium Pharmaceuticals, Inc. (ATNM: NYSE MKT) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Client News

  1. Oct 16 2017 Actinium Pharmaceuticals to Present at BIO Investor Forum
  2. Oct 4 2017 Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
  3. Sep 20 2017 Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
  4. Sep 13 2017 Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting